Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam in Pathological Gambling
NCT01215357Phase 2Completed
- Sponsor
- Emalex Biosciences
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ecopipam in gambling disorder (GD), sponsored by Emalex Biosciences. Started Oct 2010; status: completed.
02
Drugs
ecopipam
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on NCT01215357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215357.